I am a
Home I AM A Search Login

Papers of the Week

2022 Dec 08

Rheumatol Ther

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.


Yoo W-H, Kang Y M, Kim D W, Kang E H, Lee Y-A, Suh C-H, Sung Y-K, Lee S-H, Gu D-H, Lee J, Choe J-Y
Rheumatol Ther. 2022 Dec 08.
PMID: 36482248.


SB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis factor inhibitor, to treat various autoimmune diseases including axial spondylarthritis (axSpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and plaque psoriasis (PsO). This post-marketing surveillance (PMS) study of SB4 investigated safety and effectiveness in routine clinical practice and is part of the drug approval process in Korea.